Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study

BACKGROUND: In a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg dose. The primary objective of the study was to assess the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Landy, Stephen, Munjal, Sagar, Brand-Schieber, Elimor, Rapoport, Alan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093827/
https://www.ncbi.nlm.nih.gov/pubmed/30112726
http://dx.doi.org/10.1186/s10194-018-0881-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093827/
https://www.ncbi.nlm.nih.gov/pubmed/30112726
http://dx.doi.org/10.1186/s10194-018-0881-z

Ejemplares similares